De Geest, Sabina http://orcid.org/0000-0003-0654-4052
Valenta, Sabine
Ribaut, Janette
Gerull, Sabine
Mielke, Juliane
Simon, Michael
Bartakova, Jana
Kaier, Klaus
Eckstein, Jens
Leppla, Lynn
Teynor, Alexandra
,
Funding for this research was provided by:
B. Braun Foundation, Germany (EMID:4d6439e3d89d4c8e)
Jose Carreras Foundation, Germany (DJCLS 20 R/2018)
Swiss Cancer Research foundation, Switzerland (HSR-4362-11-2017)
Foundation to combat cancer, Switzerland (Project-ID: 470)
Werner and Hedy Berger-Janser Foundation, Switzerland (11/2020)
Foundation Nursing Science Switzerland (3052-2021)
Bavarian State Ministry of Science and the Arts, German Federal Ministry of Education and Research, Germany (IX.2-M7426.6.6/6/2)
Article History
Received: 1 June 2022
Accepted: 5 July 2022
First Online: 20 August 2022
Declarations
:
: This study was approved by the responsible ethics committee, Ethics Committee Northwest and Central Switzerland (EKNZ: 2021–00202) and monitored by the Clinical Trial Unit (CTU), University Hospital Basel, Switzerland (ExternalRef removed), who are. Independent from the sponsor and competing interests: An initial site visit and in total three monitoring visits will be conducted within the trial phase by the responsible monitor of the CTU. Any adverse events and other unintended effects of trial interventions will be directly reported to ethic committee and CTU.
: Not applicable.
: The authors declare that they have no competing interests.